SLC6A15

Sodium-dependent neutral amino acid transporter B(0)AT2 · Q9H2J7 · SLC6A15 on Sugi Atlas →

1,820 patent compounds predicted against SLC6A15, 1,279 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9133053	0.84	17/20
SCHEMBL8889765	1.00	16/20
SCHEMBL8880029	0.98	16/20
SCHEMBL8878121	0.86	16/20
SCHEMBL8879837	0.83	16/20
Loratadine (SCHEMBL988993)	0.82	16/20
SCHEMBL8879258	0.82	16/20
SCHEMBL8889578	0.79	16/20
SCHEMBL8877992	0.76	16/20
SCHEMBL6177907	0.69	16/20
SCHEMBL6179203	0.67	16/20
Loratadine (SCHEMBL4596)	1.00	15/20
Loratadine (SCHEMBL3862958)	1.00	15/20
SCHEMBL8877554	1.00	15/20
SCHEMBL8878098	1.00	15/20
Loratadine (SCHEMBL2166756)	0.98	15/20
Loratadine (SCHEMBL2419280)	0.94	15/20
Loratadine (SCHEMBL5968263)	0.90	15/20
SCHEMBL8878015	0.86	15/20
Loratadine (SCHEMBL7811035)	0.86	15/20

Clinical trials — most relevant to SLC6A15 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Kuvan on Melatonin Secretion	PHASE4	COMPLETED
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital	nan	NOT_YET_RECRUITING
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)	nan	UNKNOWN
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy	nan	NOT_YET_RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Brain P-gp and Inflammation in People With Epilepsy	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract	nan	COMPLETED
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	nan	UNKNOWN
Stem Cell Study of Genetics and Drug Addiction	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC6A15 binder may also engage these)

Protein	Name	Similarity
Q8BG16	—	1.000	Q8BG16 →
Q9XS59	—	1.000	Q9XS59 →
Q8BJI1	—	1.000	Q8BJI1 →
P31662	—	1.000	P31662 →
Q08469	—	1.000	Q08469 →
B4JMC1	—	1.000	B4JMC1 →
Q5R9C2	—	1.000	Q5R9C2 →
A7Y2X0	—	1.000	A7Y2X0 →
Q9H1V8	—	0.999	Q9H1V8 →
Q9XT49	—	0.998	Q9XT49 →
Q8VDB9	—	0.998	Q8VDB9 →
P51905	—	0.998	P51905 →
Q761V0	—	0.997	Q761V0 →
Q9JMA9	—	0.997	Q9JMA9 →
P48057	—	0.996	P48057 →
SLC6A3	Sodium-dependent dopamine transporter	0.996	landscape →
SLC6A4	Sodium-dependent serotonin transporter	0.996	landscape →
Q9MZ34	—	0.996	Q9MZ34 →
Q2A865	—	0.996	Q2A865 →
Q7K4Y6	—	0.995	Q7K4Y6 →
Q00589	—	0.995	Q00589 →
P31650	—	0.995	P31650 →
Q9W4C5	—	0.995	Q9W4C5 →
O35899	—	0.995	O35899 →
Q29GB8	—	0.994	Q29GB8 →
B4MEG2	—	0.994	B4MEG2 →
G5EBM5	—	0.994	G5EBM5 →
Q9MYX0	—	0.993	Q9MYX0 →
SLC6A19	Sodium-dependent neutral amino acid transporter B(0)AT1	0.993	landscape →
Q8VBW1	—	0.993	Q8VBW1 →